• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • Ancer®
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us

POSTER: Enhancing Immunogenicity Risk Assessment: Leveraging ISPRI for Bispecific Antibody Analysis

by Elena Iemma | Apr 21, 2025

Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches

by Elena Iemma | Mar 25, 2025

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

by Elena Iemma | May 23, 2024

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

by Elena Iemma | May 23, 2024

Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

Poster: Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)

by Elena Iemma | Sep 21, 2023

Prospectively Assessing the Immunogenic Risk of Potential Synthetic Peptide Impurities in silico with the What-if Machine (WhIM)
« Older Entries

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.